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Outcome Assessments: Conceptual Foundation—Report of
The ISPOR Clinical Outcomes Assessment – Emerging Good
Practices For Outcomes Research Task ForceThe International Society for Pharmacoeconomics and Outcomes
Research (ISPOR) Task Force for Clinical Outcome Assessments
(COAs) has presented a clear conceptual foundation for the
development of precise clinical trial instruments and end points.
This article reinforces the “begin with the end in mind” thought
processes for clinical trial development, highlighting the need to
match clinical outcomes with the concept of interest (COI) and
the context of use (COU) to maximize the potential to demon-
strate a meaningful treatment beneﬁt. The value of integrating
the clearly thought out conceptual nature of clinical outcomes
into clinical trial development is not to be underestimated.
As billions of dollars are spent annually in drug development,
the impetus to select the correct outcome for a clinical trial to
maximize the likelihood of success is paramount. The ISPOR COA
conceptual foundation presents much thoughtful work on the
considerations of end point selection from a conceptual basis. In
this report, the task force authors clearly review and outline the
alphabet soup of acronyms that prevails when describing out-
comes: COI, COA, COU, patient-reported outcomes (PROs),
clinician-reported outcomes (ClinROs), observer-reported out-
comes (ObsROs), and performance outcomes (PerfOs). These con-
cepts are mentioned by the Food and Drug Administration (FDA) in
its qualiﬁcation guidance [1], but through this report, they have
been described and illustrated in the context of outcome (instru-
ment) and end point selection. Clearly thinking through what
outcomes are best suited for a clinical trial is as critical to success
as the assurance of strong measurement properties to ensure that
the clinical outcomes are measured with precision.
Several key points are highlighted in this task force report. First,
the deﬁnition of treatment beneﬁt as a “favorable effect on a
meaningful aspect of how a patient feels or functions in their life
or on their survival” is nuanced with patient-centricity by consider-
ing a treatment as not beneﬁcial unless its effect is “meaningful” to
the patient. A word of caution to the literal interpretation of this
deﬁnition is warranted because not every beneﬁcial outcome is
necessarily deemed “meaningful” to patients. Treatments of asymp-
tomatic conditions such as hypertension and hypercholesterolemia
can be quite beneﬁcial to patients, but patients may not necessarily
view reduced blood pressure or lipid levels as “meaningful” despite
the demonstrated effects of reduced morbidity and mortality.
Although the lack of “meaningfulness” to patients is likely seen
in nonadherence to such medications, this in no way reﬂects lack
of treatment beneﬁt. In addition, many patients have varying
deﬁnitions of meaningful, with some being highly unrealistic.ial support: The authors have no other ﬁnancial rIndeed, it is difﬁcult for patients to abstractly express and quantify
a meaningful treatment beneﬁt outside of experiencing the treat-
ment [2]. Research in goal setting of patient expectations has
demonstrated that if the patients’ expectations of treatment are
realistic, they experience more “meaningful” outcomes [3,4]. Thus,
although the deﬁnition of treatment beneﬁt proposed by the task
force is useful and patient-centric, the need for patient mean-
ingfulness in a pure sense may be a bar set too high for drug
development. Perhaps an important nuance to this deﬁnition is that
treatment beneﬁts need to be relevant to patients’ lives to be deemed
beneﬁcial. Engaging patients in the drug development process will
help in the selection of patient-relevant and meaningful end points.
Following meaningful change is the discussion on interpret-
ability, the ability to interpret the relationship between the
outcome results and the treatment beneﬁt. The task force report
presents this as a measurement property; however, there is no
speciﬁc mention of interpretability as a measurement property
within the 2009 FDA guidance on PRO development or the
qualiﬁcation guidance [1,5]. Indeed, a measure without meaning
and relevance is not a measure to be used as an outcome;
however, the interpretability of a measure is contingent upon
the COU, as noted by the task force. Thus, when selecting a COA,
an understanding of how the outcomes are interpreted is essen-
tial, but one needs to be careful because the COU may alter the
measure’s literal interpretation (e.g., a reduction of one incon-
tinence episode per day for a person with mild incontinence may
mean a cure, whereas a reduction of one incontinence episode
per day for someone with six or seven episodes per day may not
be a “meaningful” beneﬁt). Many times when selecting an end
point, the true interpretability of the end point as meaningful to a
patient within a speciﬁc COU is not known. Consequently,
interpretability does not necessarily transfer with each COU,
which is a point that has been well illustrated by this article.
Athough the task force appropriately acknowledges the dis-
cussion of the measurement properties of validity, reliability, and
responsiveness to previous references, it is important to recog-
nize that these properties are just as essential to consider when
selecting an outcome as interpretability. Without a reliable, valid,
and responsive outcome measure, the data are meaningless to
interpret. As noted by the task force report, the outcome measure
should be related to the COI and well related to the meaningful
health aspect (highlighting the need for regulatory semantics in
matching the COI name with the COA name to enhance consis-
tency when deﬁning outcome).elationships to disclose.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 7 3 9 – 7 4 0740An area of discussion that is missing in this task force report
is related to personalized medicine and adaptive testing of COA,
which will yield a greater diversity in end points. Given the
heterogeneity of some diseases, there is no one unique end point;
thus, consideration of “bringing your own” end point or most
bothersome symptom as a key end point has emerged in FDA’s
recent guidance for acute treatment of migraine [6]. Although this
type of end point certainly encapsulates the essence of “mean-
ingfulness” to patient aspect, it leads to a quagmire of conceptual
and statistical issues that need to be considered and merit
further investigation and discussion.
In conclusion, we applaud the ISPOR task force’s work in
producing this report that clariﬁes and links key terms for the
development and selection of clearly focused, reliable, valid, and
responsive COAs capable of demonstrating meaningful treatment
beneﬁts in drug and medical device clinical trials. The future value
of this guide should be conﬁrmed in improved end point precision;
interpreting the importance of a statistically signiﬁcant change over
time will continue to require careful insight on the meaningfulness
within the COU that incorporates patient input.
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